Drugs / auto-BM-MNC
auto-BM-MNC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05631444 | Jan 2019 → Sep 2020 | diabetes mellitus, limb ischemia | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | auto-BM-MNC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631444 ↗ |
| Known as | BM-MNC | “autologous bone marrow mononuclear cells (BM-MNC)” NCT05631444 ↗ |
| Known as | Bone marrow mononuclear cells | “autologous bone marrow mononuclear cells (BM-MNC)” NCT05631444 ↗ |
| Modality | Cell therapy | “Biological: Cell-based therapy” NCT05631444 ↗ |
| Route | Other | “administered into the periadventitial layer of the arterial walls under eco-Doppler guidance” PMID 37626416 ↗ Aug 2023 |